fda compounding glp-1 is facing increased scrutiny, and the path forward is far from clear., ㅤ, Recent messaging has raised questions across the industry, with potential enforcement around GLP-1 APIs FDA GLP-1 Compounding Crackdown

This can result in fatigue, irritability, and difficulty concentrating during the day

Several medications are available, and some may lead to more consistent results depending on how they are used

Patients with T2DM and a high cardiovascular risk might reduce their risk of atherosclerotic events via the use of GLP-1RA (30)

GLP-1RA vs DPP-4i use and rates of hyperkalemia and RAS blockade discontinuation in type 2 diabetes

1c,d) and was previously suggested as a candidate for a potential activator site, first, because its positive charge might stabilize or bind GSH as GS , and, second, because of its evolutionary conserved position that is equivalent to the GSH-interacting catalytic residue of glutathione transferases 3

highlighting its potential development as neuroprotective agent